Series A · Biotech · Uppsala, Sweden · Founded 2016 · 11–20 employees
Ilya Pharma is developing a novel immunotherapy platform using engineered lactic acid bacteria as live vectors to deliver therapeutic proteins directly to target tissues. Their lead asset ILP100-Topical for wound healing has shown promising safety data in Phase 1 trials and received FDA Rare Pediatric Disease Designation for SAVI. The company has secured over EUR 5 million in EU grants including H2020 SME Phase 2 funding and EIC Accelerator grants. Co-founded by Wallenberg Scholar Professor Mia Phillipson, the company represents a breakthrough in local-acting immunotherapies for skin wounds, inflammatory bowel disease, and multi-drug resistant infections.
No open roles listed right now.